KemPharm Starts Phase 2 Trial for the Treatment of Idiopathic Hypersomnia

 Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severity of “brain fog”

Interim efficacy and safety data expected as early as Q3 2023

https://www.biospace.com/article/releases/kempharm-announces-initiation-of-phase-2-clinical-trial-investigating-kp1077-for-the-treatment-of-idiopathic-hypersomnia-ih-/